CN116407651B - Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine - Google Patents
Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine Download PDFInfo
- Publication number
- CN116407651B CN116407651B CN202310533478.XA CN202310533478A CN116407651B CN 116407651 B CN116407651 B CN 116407651B CN 202310533478 A CN202310533478 A CN 202310533478A CN 116407651 B CN116407651 B CN 116407651B
- Authority
- CN
- China
- Prior art keywords
- mrwvyhpfq
- polypeptide
- tumor
- cancer
- medicament
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 108090000765 processed proteins & peptides Proteins 0.000 title claims abstract description 39
- 229920001184 polypeptide Polymers 0.000 title claims abstract description 38
- 102000004196 processed proteins & peptides Human genes 0.000 title claims abstract description 38
- 239000003814 drug Substances 0.000 title claims abstract description 32
- 238000003745 diagnosis Methods 0.000 title claims abstract description 18
- 206010028980 Neoplasm Diseases 0.000 title abstract description 62
- 150000001413 amino acids Chemical class 0.000 claims abstract description 15
- 125000003275 alpha amino acid group Chemical group 0.000 claims abstract 2
- 239000007850 fluorescent dye Substances 0.000 claims description 23
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 16
- 201000007270 liver cancer Diseases 0.000 claims description 16
- 208000014018 liver neoplasm Diseases 0.000 claims description 16
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 16
- 201000002528 pancreatic cancer Diseases 0.000 claims description 16
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 16
- 238000000799 fluorescence microscopy Methods 0.000 claims description 12
- 206010006187 Breast cancer Diseases 0.000 claims description 11
- 208000026310 Breast neoplasm Diseases 0.000 claims description 11
- 239000003153 chemical reaction reagent Substances 0.000 claims description 8
- 238000012632 fluorescent imaging Methods 0.000 claims description 6
- 238000001356 surgical procedure Methods 0.000 claims description 3
- 238000004519 manufacturing process Methods 0.000 claims 2
- 210000004185 liver Anatomy 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 11
- 238000001727 in vivo Methods 0.000 abstract description 7
- 230000004060 metabolic process Effects 0.000 abstract description 3
- 239000002872 contrast media Substances 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 9
- 210000001519 tissue Anatomy 0.000 description 8
- 239000000243 solution Substances 0.000 description 7
- 238000011580 nude mouse model Methods 0.000 description 6
- 230000003287 optical effect Effects 0.000 description 6
- 241000699660 Mus musculus Species 0.000 description 5
- 208000003721 Triple Negative Breast Neoplasms Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 208000022679 triple-negative breast carcinoma Diseases 0.000 description 4
- 101100394734 Aspergillus oryzae (strain ATCC 42149 / RIB 40) hepG gene Proteins 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000001819 mass spectrum Methods 0.000 description 3
- 238000010172 mouse model Methods 0.000 description 3
- 239000002504 physiological saline solution Substances 0.000 description 3
- 239000011347 resin Substances 0.000 description 3
- 229920005989 resin Polymers 0.000 description 3
- 238000011282 treatment Methods 0.000 description 3
- 210000003462 vein Anatomy 0.000 description 3
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 238000004949 mass spectrometry Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000005303 weighing Methods 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 1
- 239000007821 HATU Substances 0.000 description 1
- 206010061213 Iatrogenic injury Diseases 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 102000008022 Proto-Oncogene Proteins c-met Human genes 0.000 description 1
- 108010089836 Proto-Oncogene Proteins c-met Proteins 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012295 chemical reaction liquid Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 239000000975 dye Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 210000002751 lymph Anatomy 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 238000000034 method Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 239000003068 molecular probe Substances 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 238000002559 palpation Methods 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000002271 resection Methods 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000010532 solid phase synthesis reaction Methods 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- ZGYICYBLPGRURT-UHFFFAOYSA-N tri(propan-2-yl)silicon Chemical compound CC(C)[Si](C(C)C)C(C)C ZGYICYBLPGRURT-UHFFFAOYSA-N 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 238000003041 virtual screening Methods 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0032—Methine dyes, e.g. cyanine dyes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
The invention provides application of polypeptide MRWVYHPFQ in tumor diagnosis medicaments, and belongs to the technical field of fluorescent contrast agents. The polypeptide MRWVYHPFQ provided by the invention is applied to tumor diagnosis medicines, and the amino acid sequence of the polypeptide MRWVYHPFQ from the C end to the N end is Met-Arg-Trp-Val-Tyr-His-Pro-Phe-Gln in sequence, wherein all the amino acids are L-type natural amino acids. The application of the polypeptide MRWVYHPFQ in the tumor diagnosis medicament provided by the invention specifically targets and identifies various tumors in vivo, has high tumor/normal tissue signal-to-noise ratio, and can be used for tumor boundary accurate positioning and tumor operation navigation. Meanwhile, the polypeptide MRWVYHPFQ is fast in metabolism in vivo, high in safety and high in clinical application prospect.
Description
Technical Field
The invention relates to the technical field of fluorescent contrast agents, in particular to application of polypeptide MRWVYHPFQ in tumor diagnosis medicines.
Background
Malignant tumors have been a major public health problem worldwide, with about 27000 people dying from cancer every day worldwide. Early effective screening and accurate treatment are important links in reducing cancer death. Despite the increasing diversity of cancer treatments, surgical excision remains the primary treatment for most solid tumors, even the sole treatment. The fundamental goal of tumor surgery is to completely ablate tumor tissue to avoid recurrence while preserving healthy tissue to the maximum to avoid unnecessary iatrogenic injury. Thus, there is a need to accurately identify primary and metastatic tumors and healthy tissues such as nerves, blood vessels, and lymph in the vicinity thereof during surgery. Because the microscopic lesions of most early and progressive tumors do not have typical morphological structures, the distinction between tumor and healthy tissue often cannot be accurately identified by visual observation and hand palpation by the surgeon.
The operation navigation system is based on optical molecular imaging technology to perform real-time dynamic imaging on tumor and other focus tissues, and can complete multi-angle, high-flux and dynamic continuous acquisition of structural and functional image data. With the development of optical surgical navigation systems, it is increasingly important to guide tumor resection intraoperatively. However, the development of optical molecular probes which can be used in clinical operation navigation systems and have various tumor targeting detection functions is insufficient.
Disclosure of Invention
In view of the above, the invention aims to provide an application of the polypeptide MRWVYHPFQ in tumor diagnosis drugs, and the application of the polypeptide MRWVYHPFQ in tumor diagnosis drugs specifically targets and identifies various tumors in vivo, has high tumor/normal tissue signal-to-noise ratio, can be used for tumor boundary accurate positioning and tumor intraoperative navigation, and has a higher clinical application prospect.
In order to achieve the above object, the present invention provides the following technical solutions:
an application of a polypeptide MRWVYHPFQ in tumor diagnosis medicaments, wherein the amino acid sequence from the C end to the N end of the polypeptide MRWVYHPFQ is as follows:
Met-Arg-Trp-Val-Tyr-His-Pro-Phe-Gln；
wherein all the amino acids are L-type natural amino acids.
Preferably, the polypeptide MRWVYHPFQ is covalently coupled to a fluorescent imaging group to provide a fluorescent diagnostic reagent.
Preferably, the fluorescent imaging group is a near infrared one-region fluorescent dye and/or a near infrared two-region fluorescent dye.
Preferably, the near infrared one-region fluorescent dye is one or more of IRDye800, IR820, cy7.5, cy7, ICG and Cy5.5; the near infrared two-region fluorescent dye is one or more of ICG, IR-1061 and CH 1055.
Preferably, the tumor is liver cancer, pancreatic cancer or breast cancer.
Preferably, the tumor diagnosis medicine is a tumor boundary accurate positioning medicine and/or an intraoperative navigation fluorescence imaging medicine.
The beneficial technical effects are as follows: the invention provides application of polypeptide MRWVYHPFQ in tumor diagnosis medicines, wherein the amino acid sequence of the polypeptide MRWVYHPFQ from the C end to the N end is Met-Arg-Trp-Val-Tyr-His-Pro-Phe-Gln in sequence, and all amino acids are L-type natural amino acids. The application of the polypeptide MRWVYHPFQ in the tumor diagnosis medicament provided by the invention specifically targets and identifies various tumors in vivo, has high tumor/normal tissue signal-to-noise ratio, and can be used for tumor boundary accurate positioning and tumor operation navigation. Meanwhile, the polypeptide MRWVYHPFQ is fast in metabolism in vivo, high in safety and high in clinical application prospect.
Drawings
FIG. 1 shows the chemical structure of fluorescent diagnostic reagents Cy7.5-MRWVYHPFQ;
FIG. 2 is a mass spectrum of fluorescent diagnostic reagents Cy7.5-MRWVYHPFQ;
FIG. 3 is a 4h fluorescence imaging diagram of the prepared fluorescent compound Cy7.5-MRWVYHPFQ in tumor-bearing mice. Wherein A is fluorescence imaging of liver cancer MHCC 97-H; b is fluorescence imaging of liver cancer HepG 2; c is fluorescence imaging of pancreatic cancer CFPAC-1; d is fluorescence imaging of pancreatic cancer SW 1990; e is fluorescence imaging of triple negative breast cancer MDA-MB-231.
Description of the embodiments
The invention provides an application of polypeptide MRWVYHPFQ in tumor diagnosis drugs, wherein the amino acid sequence of polypeptide MRWVYHPFQ from the C end to the N end is as follows:
Met-Arg-Trp-Val-Tyr-His-Pro-Phe-Gln；
wherein all the amino acids are L-type natural amino acids.
In the invention, the sequence of the polypeptide is obtained by computer-aided drug virtual screening based on modeling of a C-Met protein receptor with high expression of tumor. The polypeptide MRWVYHPFQ provided by the invention adopts L-type natural amino acids, and has the advantages of rapid metabolism in vivo, high safety and higher clinical application prospect.
In the invention, the polypeptide MRWVYHPFQ needs to be covalently coupled with a fluorescent imaging group to obtain a fluorescent diagnostic reagent; the fluorescent imaging group is a near infrared first-region fluorescent dye and/or a near infrared second-region fluorescent dye; the near infrared one-region fluorescent dye is preferably one or more of IRDye800, IR820, cy7.5, cy7, ICG and Cy5.5, and more preferably Cy7.5; the present invention is directed to a polypeptide comprising-COOH in Cy7.5 and-NH of methionine Met in polypeptide MRWVYHPFQ 2 The chemical structure of the fluorescence diagnosis reagent Cy7.5-MRWVYHPFQ and Cy7.5-MRWVYHPFQ prepared by amide bond connection is shown in figure 1; the near infrared two-region fluorescent dye is preferably one or more of ICG, IR-1061 and CH 1055.
In the present invention, the tumor is preferably liver cancer, pancreatic cancer or breast cancer. The application of the polypeptide MRWVYHPFQ provided by the invention in tumor diagnosis drugs specifically targets and identifies various tumors in vivo, and has high tumor/normal tissue signal-to-noise ratio.
In the invention, the tumor diagnosis medicine is a tumor boundary accurate positioning medicine and/or an intraoperative navigation fluorescence imaging medicine. The tumor diagnosis medicine can be used for accurate positioning of tumor boundaries and navigation in tumor operation, is suitable for preparing tumor operation navigation reagents, is used for guiding surgeons to accurately cut tumor cells, and has higher clinical application prospect.
For a better understanding of the present invention, the following examples are further illustrated, but are not limited to the following examples. Materials, reagents and the like used in the examples and test examples of the present invention can be obtained commercially unless otherwise specified; the methods used in the examples and test examples of the present invention are conventional methods unless otherwise specified.
In the present invention, the MQ polypeptide MRWVYHPFQ was synthesized by solid phase method from the state of the hangzhou solid-state biotechnology limited, and the near infrared fluorescent dye was purchased from the med chemexpress company.
Example 1 Synthesis of Cy7.5-MRWVYHPFQ
A Ramage Amide AM resin resin with Loading of 0.45mmol/g was selected and Fmoc protecting groups were removed after swelling. According to the polypeptide sequence: MRWVYHPFQ the coupling is carried out from the C end to the N end in sequence until Fmoc-M-COOH, and all the amino acids are Fmoc-protected alpha amino groups. And (3) detecting the molecular weight of the polypeptide by mass spectrometry after cutting a small sample, determining that the Fmoc-MRWVYHPFQ mass spectrum of the polypeptide is correct, reacting a lysate (TFA: triisopropylsilane: water=95:2.5:2.5) with linear peptide resin to obtain MRWVYHPFQ with all side chain protecting groups removed, and purifying to obtain a polypeptide pure product.
Purified polypeptide MRWVYHPFQ was dissolved in DMF and then 1.2-fold molar amount of near infrared dye cy 7.5-carboxyl, 1.5-fold molar amount of HATU and 3-fold molar amount of DIPEA were added and reacted in the dark for 1 hour. After the reaction is finished, the Cy7.5-MRWVYHPFQ reaction liquid is purified by preparative chromatography, qualified liquid is separated, and after the liquid is collected, evaporated and freeze-dried, the liquid is confirmed to be the target compound Cy7.5-MRWVYHPFQ by ESI-MS mass spectrometry analysis.
The mass spectrum results are shown in FIG. 2, ESI-MS: [ M-2H] 2- = 1094.3 and [ M-3H] 3- =730.0。
Examples
Liver cancer MHCC97-H, hepG tumor-bearing mice are obtained by subcutaneously inoculating liver cancer MHCC97-H, hepG cells (purchased from Biyun biotechnology Co., ltd.) into normal tumor-bearing mice.
Fluorescence imaging of the prepared fluorescent compound Cy7.5-MRWVYHPFQ in liver cancer MHCC97-H, hepG tumor-bearing mice:
taking the fluorescent compound Cy7.5-MRWVYHPFQ prepared in the example 1, and preparing a solution of Cy7.5-MRWVYHPFQ with the concentration of 100nmol/mL by using physiological saline;
3 nude mice (weight about 22 g) of liver cancer MHCC97-H, hepG2 were each taken, 0.1mL (about 10 nmol) of the solution of Cy7.5-MRWVYHPFQ was injected into the tail vein of the nude mice, and optical signal collection was performed at 1h, 2h, 4h, 6h, 8h, 10h and 12h after injection. The distribution of the fluorescent drug in the model mice and the enrichment of the tumor area were observed, and the results of 4h are shown in fig. 3A and 3B. As can be seen from FIGS. 3A and 3B, the fluorescent probe Cy7.5-MRWVYHPFQ can specifically target liver cancer (MHCC 97-H and HepG 2) sites.
Examples
Pancreatic cancer CFPAC-1, SW1990 tumor-bearing mice were obtained by subcutaneously inoculating normal tumor-bearing mice with cells of pancreatic cancer CFPAC-1, SW1990 (purchased from the company of the bio-technology of bi cloud).
Fluorescence imaging of the prepared fluorescent compound Cy7.5-MRWVYHPFQ in pancreatic cancer CFPAC-1, SW1990 tumor-bearing mice:
taking the fluorescent compound Cy7.5-MRWVYHPFQ prepared in the example 1, and preparing a solution of Cy7.5-MRWVYHPFQ with the concentration of 100nmol/mL by using physiological saline;
3 nude mice (weighing about 22 g) with pancreatic cancer CFPAC-1 and SW1990 were each injected with 0.1mL (about 10 nmol) of solution of Cy7.5-MRWVYHPFQ into the tail vein of the nude mice, and optical signal collection was performed at 1h, 2h, 4h, 6h, 8h, 10h and 12h after injection. The distribution of the fluorescent drug in the model mice and the enrichment of the tumor area were observed, and the 4h results are shown in fig. 3C and 3D. As can be seen from FIGS. 3C and 3D, fluorescent probes Cy7.5-MRWVYHPFQ specifically target pancreatic cancer (CFPAC-1, SW 1990) sites.
Examples
Triple negative breast cancer MDA-MB-231 tumor-bearing mice were obtained by subcutaneously inoculating triple negative breast cancer MDA-MB-231 cells (purchased from Biyun Tian Biotechnology Co., ltd.) into normal tumor-bearing mice.
Fluorescence imaging of the prepared fluorescent compound Cy7.5-MRWVYHPFQ in a triple negative breast cancer MDA-MB-231 tumor-bearing mouse:
taking the fluorescent compound Cy7.5-MRWVYHPFQ prepared in the example 1, and preparing a solution of Cy7.5-MRWVYHPFQ with the concentration of 100nmol/mL by using physiological saline;
3 breast cancer MDA-MB-231 nude mice (weighing about 22 g) were taken, 0.1mL (about 10 nmol) of the solution of Cy7.5-MRWVYHPFQ was injected into the tail vein of each nude mouse, and optical signal acquisition was performed at 1h, 2h, 4h, 6h, 8h, 10h and 12h after injection. The distribution of the fluorescent drug in the model mice and the enrichment of the tumor area were observed, and the 4h results are shown in fig. 3E. As can be seen in FIG. 3E, fluorescent probes Cy7.5-MRWVYHPFQ specifically target the breast cancer (MDA-MB-231) site.
The foregoing is merely a preferred embodiment of the present invention and it should be noted that modifications and adaptations to those skilled in the art may be made without departing from the principles of the present invention, which are intended to be comprehended within the scope of the present invention.
Claims (5)
1. An application of polypeptide MRWVYHPFQ in preparing a medicine for diagnosing liver cancer, pancreatic cancer or breast cancer is characterized in that the amino acid sequence from C end to N end of polypeptide MRWVYHPFQ is as follows:
Met-Arg-Trp-Val-Tyr-His-Pro-Phe-Gln；
wherein all the amino acids are L-type natural amino acids.
2. The use of the polypeptide MRWVYHPFQ according to claim 1 for the preparation of a medicament for diagnosing liver cancer, pancreatic cancer or breast cancer, wherein the polypeptide MRWVYHPFQ is covalently coupled to a fluorescent imaging group to obtain a fluorescent diagnostic reagent.
3. The use of the polypeptide MRWVYHPFQ according to claim 2 for the manufacture of a medicament for the diagnosis of liver cancer, pancreatic cancer or breast cancer, wherein the fluorescent imaging group is a near infrared one-region fluorescent dye and/or a near infrared two-region fluorescent dye.
4. The use of the polypeptide MRWVYHPFQ of claim 3 for the manufacture of a medicament for diagnosing liver, pancreatic or breast cancer, wherein the near infrared one-region fluorescent dye is one or more of IRDye800, IR820, cy7.5, cy7 and Cy 5.5; the near infrared two-region fluorescent dye is one or more of ICG, IR-1061 and CH 1055.
5. The use of the polypeptide MRWVYHPFQ according to any one of claims 1 to 4 for the preparation of a medicament for diagnosing liver cancer, pancreatic cancer or breast cancer, wherein the medicament for diagnosing liver cancer, pancreatic cancer or breast cancer is a medicament for precisely locating the boundary of liver cancer, pancreatic cancer or breast cancer and/or a medicament for navigating fluorescence imaging during surgery.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310533478.XA CN116407651B (en) | 2023-05-12 | 2023-05-12 | Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202310533478.XA CN116407651B (en) | 2023-05-12 | 2023-05-12 | Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN116407651A CN116407651A (en) | 2023-07-11 |
| CN116407651B true CN116407651B (en) | 2024-03-15 |
Family
ID=87052951
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202310533478.XA Active CN116407651B (en) | 2023-05-12 | 2023-05-12 | Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN116407651B (en) |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111558050A (en) * | 2020-05-11 | 2020-08-21 | 中国药科大学 | Tumor targeting polypeptide and application thereof |
-
2023
- 2023-05-12 CN CN202310533478.XA patent/CN116407651B/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111558050A (en) * | 2020-05-11 | 2020-08-21 | 中国药科大学 | Tumor targeting polypeptide and application thereof |
| CN114796528A (en) * | 2020-05-11 | 2022-07-29 | 中国药科大学 | Tumor specific targeting polypeptide and application thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| CN116407651A (en) | 2023-07-11 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9254341B2 (en) | Methods of manufacture of pteroyl-amino acid-fluorescent dyes | |
| US10746741B2 (en) | CA IX—NIR dyes and their uses | |
| CN108949147B (en) | Molecular image probe and application thereof | |
| CN101848734B (en) | Labelled IIGF binding peptides for imaging | |
| US10918741B2 (en) | PSMA-targeting imaging agents | |
| CN113880917B (en) | Tumor high affinity peptides and application thereof | |
| CN114380786B (en) | Aminopeptidase activated chemiluminescent probe and application thereof in living body detection and surgical navigation of malignant tumors | |
| CN114933633B (en) | Natural peptide probe for specifically recognizing FGFR4 and application thereof | |
| CN112933249A (en) | PD-L1 targeted bimodal molecular probe and preparation method and application thereof | |
| US20230417754A1 (en) | Near infrared-ii probes as high affinity targeting imaging agents and uses thereof | |
| CN116407651B (en) | Application of polypeptide MRWVYHPFQ in tumor diagnosis medicine | |
| CN116063379A (en) | EphA2 targeting polypeptides and uses thereof | |
| CN116813704B (en) | Tumor targeting fluorescent molecular probe and application thereof | |
| WO2013045662A1 (en) | Peptide margin imaging agents | |
| CN107674117A (en) | The preparation method for the Dimer San A Cyclopeptide derivatives cancer of pancreas molecular probes that Cu 64 is marked | |
| CN118240017A (en) | Tumor tissue affinity peptide and application thereof | |
| CN113425859B (en) | GnRH polypeptide modified probe, preparation containing GnRH polypeptide modified probe, pharmaceutical composition containing GnRH polypeptide modified probe, and preparation method and application of GnRH polypeptide modified probe | |
| US11555821B2 (en) | CA IX-NIR dyes and their uses | |
| US20230016265A1 (en) | Psma-targeting imaging agents | |
| CN118184733A (en) | Tumor targeting polypeptide V-1-GGGK, polypeptide conjugate thereof and application thereof | |
| CN117866043A (en) | Targeting polypeptide, fluorescent contrast agent and application thereof | |
| CN117777234A (en) | Dansyl amide modified PSMA targeting compound, and preparation method and application thereof | |
| CN118078219A (en) | Near infrared fluorescence capture system, device and application | |
| CN117924419A (en) | Affinity peptide of targeted EGF receptor 2 and application thereof | |
| CN114835723A (en) | PSMA fluorescent molecular probe, preparation method and kit |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |